Biocompatibles Share Discussion Threads

[red army] 04/2/2005 19:06

Apart from the institution buying a little while ago - no.

[bonzo] 04/2/2005 18:02

No comments on today's rise? Anyone heard anything?

[drago] 04/12/2004 10:12

price keeps on nibbling up.
someone knows something?

[bipper9ers] 24/11/2004 01:23

nice tick up today, any news?

[drago] 10/11/2004 12:44

hell of a long break.

the share price holding up well so far . if the liver cancer trials were going badly
, i think we would see some selling , imho, from "insiders".

[ashrafurrahman81] 10/11/2004 10:42

all the buyers sellers gone on a break?

[drmerv] 16/10/2004 11:02

Sorry I don't have the time. Thought I might copy it from the IC website but you have to be a subscriber.

I suggest you stroll along to the WHSmith reference library and check out page 33. Alternatively you could try the new out of town reference library, at Tescos!

[drago] 16/10/2004 10:31

gosh, this thread is really hotting up!

drmerv, any chance of a presis of the tip please?

[drmerv] 16/10/2004 10:17

Full page article with Buy recommendation in this weeks Investors Chronicle.

[2bob] 15/10/2004 14:56

I have noted before that Medtronic are looking for another polymer for their stent. BII may think all is well with MDT but why would MDT say the following in open conference if that were the case?


Review of EUROPEAN SOCIETY OF CARDIOLOGY (ESC)
August 28 - September 1, 2004
Munich, Germany

Page 5

Medtronic officials offered two interesting comments:
�� Medtronic hopes to file Endeavor with the FDA on time -
in the summer 2005 by using 30-day data from Endeavor-
4 and then supplementing that with more data when it is
ready. They are having long and frequent discussions with
the FDA and are hopeful this will be allowed.
�� Medtronic plans to find a new polymer for its next
generation drug-eluting stent.

[huntie2] 04/10/2004 15:00

a sudden few sells + price drop between 2.00 - 2.30. any ideas?

[drago] 29/9/2004 12:05

thanks, i'll look it up.

[spyder] 28/9/2004 20:04

drago ...... for better, for worse - I made it up!!
More good news re-Abbott US trial date yesterday.
spyder

[drago] 27/9/2004 11:24

and another tick up this morning.

any other company with a story like this and the bb would be
heaving with rampers and derampers.

[drago] 24/9/2004 11:06

spyder,
4b4w, thats a new one on me.

see we had another tick up the other day

[spyder] 21/9/2004 19:07

Yes, drago, very much so 4b4w.

[drago] 21/9/2004 10:37

spyder,
many thanks for your reply.
much appreciated.

are you in?

[ntv] 19/9/2004 18:37

nice little run up in the last couple of days toa new recent high

[spyder] 17/9/2004 08:19

This might help answer your question drago .....

Reasons for the recent rise in share price?

The following comments from recent announcements might help to explain:

CE Mark has been granted for the Drug-Eluting Bead / doxorubicin combination with a planned European launch with the final PRECISION data, expected in H2 2005.

First PRECISION data to be presented at the Cardiovascular and Interventional Radiology Society of Europe Conference (CIRSE) on 26 September 2004 entitled 'Drug Delivery Beads for Embolisation'.

The Chairman says - 'The drug-eluting bead concept is looking increasingly promising and the FDA decision to review it as a combination product medical device is very good news' the interim statement goes on to say that this offers the prospect of less time and less cost than originally planned. The Company expects 2004 operating cash expenditure to be around £9m, a reduction from the previously indicated expectation of £10m. This is as a result of the positive outcome of the US regulatory approach adopted for the Drug-Eluting Bead.

The Company established ten items that were planned for announcement during the course of the year, each of which was expected to contribute to the creation of shareholder value. All of these are expected to be achieved.

PRECISION drug-eluting bead trial
- completion of recruitment
- first data by year-end
• Strengthening of the pipeline with two new programmes:
- pre-clinical development for a second drug-eluting bead product
- additional clinical trial for the doxorubicin-eluting bead
• Bead Block used in its 100th hospital
• Launch of Bead Block in Asia (excluding Japan)
• Signing of new PC Technology licence agreement with a global medical
device company
• Announcement of drug-eluting stent trial data expected from Medtronic
• Announcement expected from Abbott regarding drug-eluting stent clinical trials
• Further developments in the Isostent litigation

The Company has signed a Letter of Intent for a new PC Technology Licence and expects to conclude a definitive agreement before the end
of the year. This has previously been flagged up as being with a major US medical device company. A number of feasibilities studies are also scheduled for the second half.

Expansion of the drug eluting bead programme to other solid tumours is under discussion with key European physicians.
A combination of IRINOTECAN and embolic beads will focus on the
treatment of colorectal liver metastases and a combination of embolic beads and IBUPROFEN will be targeted at pain relief. The most significant clinical application for pain relief is likely to be in UFE but the concept will also be considered for cancer. Clinical evaluation for these programmes is likely to start outside the US next year.

Abbott vascular devices has enrolled the first patient in clinical trial of the zomaxxtm drug-eluting coronary stent an important milestone. The stent combines a PC coating with ABT 578 on an innovative 'tri-metal' stent composite material. The ZOMAXX I trial is a 400-patient prospective randomized clinical trial that will be conducted in more than 30 centers in Europe, Australia and New Zealand. Abbott's President said "Along with our plans for a North American pivotal trial, the start of ZOMAXX I demonstrates our commitment to becoming a leading player in drug-eluting stents, one of the fastest growing areas in medical technology".

Robert Whitbourn, M.D., of St. Vincent's Hospital in Melbourne, Australia, enrolled the first patient in the ZOMAXX I trial. "I am looking forward to enrolling additional patients in this important trial. Based on in vitro studies, the ZoMaxx stent design demonstrated excellent flexibility, contributing to a high level of deliverability. I am eager to test the device clinically," said Dr. Whitbourn.

The TriMaxx stent is anticipated to be the next evolution in metallic stents with its unique tri-layer composite of stainless steel and tantalum, and its ultra-low crossing profile - designed to facilitate placement of the stent in the artery. This tri-layer composite material allows for extremely thin struts (mesh scaffolding) while maintaining optimal visibility via angiography (a form of X-ray). The TriMaxx stent also utilizes a novel stent pattern with Apex Ring Control (A.R.C.TM), which is designed to maximize flexibility and deliverability while maintaining ideal scaffolding and vessel wall coverage for uniform drug delivery.

A key component of the ZoMaxx stent is PharmacoatTM, a unique formulation of phosphorylcholine polymer coating that contains an extra cap-coat - an additional layer of coating that enables the drug to elute over time. In vitro studies show that Pharmacoat acts as a versatile drug-eluting vehicle that provides a stable foundation for the slow, controlled release of ABT-578.

Clearly, Abbott have put a great deal of effort into developing their stent offering and their statement of intent about becoming a key player in this field is not just hot air. All good news for Biocompatibles.

Furthermore, Since 1996, 150,000 non-drug eluting phosphorylcholine-coated stents have been implanted worldwide, A useful statistic to give support to PC's safety and tolerability.

A patent has been filed for a range of novel polymers that are being evaluated in collaboration with the Centre for Medical Materials at the University of Cambridge, for the enhancement of osteointegration of orthopaedic devices.

For the first time (as far as I can recall) the company stated that if the Isostent litigation has not already been concluded by 8th May 2005, the escrow would be released under the terms of the agreement between the Company and Abbott, subject to the retention of an amount to cover any bona fide claims by Abbott under the indemnity, so whatever happens, we have a long stop date. The trial is currently underway after several postponements and pretrial conferences. Recent events have suggested that the company was clever to settle their own part of the case out of court many months ago.

The remaining disposal provision balance of £9.0m is said to represent a prudent view of the longer term warranties and indemnities relating to the disposals. This will be reviewed at the year-end and if past experience is anything to go by, could be revised downwards.

The Interim Statement reiterates that 'the Company's programmes are focused on areas of unmet or poorly met clinical needs and the Board remains optimistic about the projects for the creation of significant shareholder value'.

LAST REASON FOR THE RISE? ...................... THERE ARE ONLY 38 MILLION SHARES IN ISSUE.

spyder

[drago] 16/9/2004 21:43

oh dear me.
the share price has gone up.
220p mid


what can be happening?

[shirishg] 06/9/2004 09:25

Post removed by ADVFN

[2bob] 27/8/2004 23:03

MDT stent delays?

[run12] 26/8/2004 13:04

Red Army,

THE COUNT is currently on the SEO bb having a right old ding dong